Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McGill University

$153,862.00

Developing and clinically testing a learning algorithm that optimizes the performance of the artificial pancreas

FY 2017-18

Summary
In healthy individuals, blood sugar levels are tightly controlled by two hormones: insulin and glucagon. Secretion of insulin, avital hormone to reduce blood sugar, is lost in type 1 diabetes. Thus, type 1 diabetes patients are currently treated byintensive insulin therapy through injections or insulin pump, but glucose control remains problematic and a big challenge formost patients.Research is under steady progress by our group to develop an external artificial pancreas that automatically regulatesglucose levels in patients with type 1 diabetes. The artificial pancreas is composed of three components: a continuousglucose sensor (to measure glucose levels), infusion pumps (to infuse insulin and glucagon), and an intelligent dosingalgorithm (to control insulin and glucagon delivery based on the readings of the sensor).We have tested the artificial pancreas in several clinical trials in our clinical research facility and the results were promising.The artificial pancreas improved significantly glucose control and reduced the risk of hypoglycemia compared toconventional pump therapy. We are currently moving to longer and larger real-life studies at home.The aim of this project is to improve the artificial pancreas so that it learns the insulin needs of the patients over time andadapts as the patients insulin needs changes. We believe that this new algorithm will maintain and improve the performanceof the system in face of slow changes in patients insulin needs over weeks/months. We aim to test this new system in acomputer simulation environment then clinically in 50 adolescents for 3 weeks.The artificial has enormous potential to improve quality of life, improve health outcomes, prevent hypoglycemic events,provide confidence for physical activities and alleviate key aspect of the burden of diabetes for patients, families and healthcare providers.
Program
Collaborative Health Research Projects
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
493631-2016
Name nom
Kearney, Robert
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
153862
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Developing and clinically testing a learning algorithm that optimizes the performance of the artificial pancreas
Keyword
NSERC
Application summary
In healthy individuals, blood sugar levels are tightly controlled by two hormones: insulin and glucagon. Secretion of insulin, avital hormone to reduce blood sugar, is lost in type 1 diabetes. Thus, type 1 diabetes patients are currently treated byintensive insulin therapy through injections or insulin pump, but glucose control remains problematic and a big challenge formost patients.Research is under steady progress by our group to develop an external artificial pancreas that automatically regulatesglucose levels in patients with type 1 diabetes. The artificial pancreas is composed of three components: a continuousglucose sensor (to measure glucose levels), infusion pumps (to infuse insulin and glucagon), and an intelligent dosingalgorithm (to control insulin and glucagon delivery based on the readings of the sensor).We have tested the artificial pancreas in several clinical trials in our clinical research facility and the results were promising.The artificial pancreas improved significantly glucose control and reduced the risk of hypoglycemia compared toconventional pump therapy. We are currently moving to longer and larger real-life studies at home.The aim of this project is to improve the artificial pancreas so that it learns the insulin needs of the patients over time andadapts as the patients insulin needs changes. We believe that this new algorithm will maintain and improve the performanceof the system in face of slow changes in patients insulin needs over weeks/months. We aim to test this new system in acomputer simulation environment then clinically in 50 adolescents for 3 weeks.The artificial has enormous potential to improve quality of life, improve health outcomes, prevent hypoglycemic events,provide confidence for physical activities and alleviate key aspect of the burden of diabetes for patients, families and healthcare providers.
McGill University - $153,862 Grant (2017-18) | Canada Spends